# Study of PF-07265807 in Participants With Metastatic Solid Tumors.

> **NCT04458259** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 88 (actual)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **DRUG:** PF-07265807
- **DRUG:** Sasanlimab
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT04458259
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-24
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04458259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04458259, "Study of PF-07265807 in Participants With Metastatic Solid Tumors.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04458259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*